Amedisys Stock Price, News & Analysis (NASDAQ:AMED)

$135.43
+3.34 (+2.53 %)
(As of 09/20/2019 04:00 PM ET)
Today's Range
$131.51
Now: $135.43
$136.06
50-Day Range
$126.73
MA: $132.39
$136.39
52-Week Range
$97.38
Now: $135.43
$141.98
Volume301,078 shs
Average Volume230,670 shs
Market Capitalization$4.36 billion
P/E Ratio37.31
Dividend YieldN/A
Beta1.46
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks. Read More…

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.66 billion
Cash Flow$4.3561 per share
Book Value$15.14 per share

Profitability

Net Income$119.35 million

Miscellaneous

Employees21,000
Market Cap$4.36 billion
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.


Amedisys (NASDAQ:AMED) Frequently Asked Questions

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) released its quarterly earnings data on Wednesday, July, 31st. The health services provider reported $1.21 EPS for the quarter, topping analysts' consensus estimates of $0.97 by $0.24. The health services provider earned $492.98 million during the quarter, compared to the consensus estimate of $489.66 million. Amedisys had a return on equity of 27.23% and a net margin of 6.84%. The business's revenue for the quarter was up 19.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.00 EPS. View Amedisys' Earnings History.

When is Amedisys' next earnings date?

Amedisys is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Amedisys.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY19 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of $4.05-4.12 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.09. The company issued revenue guidance of $1.94-1.98 billion, compared to the consensus revenue estimate of $1.97 billion.

What price target have analysts set for AMED?

11 brokers have issued 1-year price objectives for Amedisys' stock. Their predictions range from $120.00 to $155.00. On average, they expect Amedisys' share price to reach $137.5533 in the next year. This suggests a possible upside of 1.6% from the stock's current price. View Analyst Price Targets for Amedisys.

What is the consensus analysts' recommendation for Amedisys?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amedisys.

Has Amedisys been receiving favorable news coverage?

News headlines about AMED stock have trended negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amedisys earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news coverage about the health services provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Amedisys.

Are investors shorting Amedisys?

Amedisys saw a drop in short interest during the month of August. As of August 31st, there was short interest totalling 1,506,900 shares, a drop of 6.4% from the July 31st total of 1,610,700 shares. Based on an average trading volume of 327,700 shares, the short-interest ratio is presently 4.6 days. Approximately 4.8% of the shares of the company are sold short. View Amedisys' Current Options Chain.

Who are some of Amedisys' key competitors?

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Netflix (NFLX), NVIDIA (NVDA), Home Depot (HD), Micron Technology (MU), QUALCOMM (QCOM), Square (SQ), Adobe (ADBE) and Honeywell International (HON).

Who are Amedisys' key executives?

Amedisys' management team includes the folowing people:
  • Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 58)
  • Mr. Scott G. Ginn, Chief Financial Officer (Age 50)
  • Mr. Christopher T. Gerard, Chief Operating Officer (Age 52)
  • Mr. David L. Kemmerly, Sr. VP of Gov. Affairs & Gen. Counsel (Age 56)
  • Ms. Sharon Brunecz, Chief HR Officer (Age 52)

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.03%), BlackRock Inc. (13.03%), Vanguard Group Inc. (10.77%), Price T Rowe Associates Inc. MD (4.19%), William Blair Investment Management LLC (3.07%) and JPMorgan Chase & Co. (2.96%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North, Scott G Ginn and Sharon Brunecz. View Institutional Ownership Trends for Amedisys.

Which institutional investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., AXA, Robeco Institutional Asset Management B.V., Great Lakes Advisors LLC, Morgan Stanley, Charles Schwab Investment Management Inc. and Schroder Investment Management Group. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Linda J Hall, Michael Paul North, Scott G Ginn and Sharon Brunecz. View Insider Buying and Selling for Amedisys.

Which institutional investors are buying Amedisys stock?

AMED stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, William Blair Investment Management LLC, Riverbridge Partners LLC, Eagle Asset Management Inc., Nuveen Asset Management LLC, Carillon Tower Advisers Inc., APG Asset Management N.V. and Marshall Wace North America L.P.. View Insider Buying and Selling for Amedisys.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $135.43.

How big of a company is Amedisys?

Amedisys has a market capitalization of $4.36 billion and generates $1.66 billion in revenue each year. The health services provider earns $119.35 million in net income (profit) each year or $3.63 on an earnings per share basis. Amedisys employs 21,000 workers across the globe.View Additional Information About Amedisys.

What is Amedisys' official website?

The official website for Amedisys is http://www.amedisys.com/.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]


MarketBeat Community Rating for Amedisys (NASDAQ AMED)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  332 (Vote Outperform)
Underperform Votes:  484 (Vote Underperform)
Total Votes:  816
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel